It’s the moment every woman dreads: A routine breast self-examination during an otherwise relaxing shower ends in the panic-inducing discovery of a lump.
Often, what happens next is a long, harrowing journey through a combination of biopsies, surgery, chemotherapy, and radiation. While it’s true that, thanks to advancements in screening and treatment, more and more women survive breast cancer, it’s also true that 80 percent of breast cancer cases have already advanced to an invasive stage at the time of diagnosis.
Today, just 20 percent of breast cancers are identified at the earliest stage, when treatment is most effective and the five-year survivorship rate hovers near 100 percent.
Carlos Barrero, MD, and Oscar Perez-Leal, MD, assistant professors in the Pharmaceutical Sciences Department at Temple University’s School of Pharmacy, wants to change all that. “I believe we can invert those numbers so we’re discovering 80 percent of breast cancers at the very earliest stage,” he says.
The research Barrero and Perez-Leal are conducting may represent a major breakthrough in breast cancer screening. Their work could lead to a simple routine blood test that detects breast cancer sooner than ever before for more women. To do this, Barrero and Perez-Leal are working on identifying a set of biomarkers for breast cancer, a specific signature of early-stage breast cancer detectable in a blood sample.
Their work on this project received funding through the Office for the Vice President of Research’s Targeted Grant Program, and the team is currently in the process of securing additional funding from the National Institutes for Health, and the National Cancer Institute. Perez-Leal is also using the knowledge gleaned from his master’s degree from the Fox School’s Innovation Management & Entrepreneurship program to turn the idea into a feasible product.
Though mammograms are a recommended cancer screening for women age 40 and older, only 65 percent of women over 40 have had one in the past two years, according to the Centers for Disease Control.
“Many women avoid mammograms because they can be uncomfortable, and because of the hassle of needing to make a separate appointment. If screening for early-stage breast cancer became a part of routine blood work, more women would be screened regularly,” says Barrero. That would likely result in more early diagnoses, more effective treatment, and ultimately more long-term cancer survivors.
Through systems biology, advances in mass spectrometry technology that allow the detection of very low concentration of proteins and metabolites, and the availability of large public datasets from thousands of breast cancer tumors, Barrero and Perez-Leal can move this cutting-edge work forward. “Most research of this kind starts with analyzing the blood sample. We start by analyzing the data,” says Perez-Leal. It’s a fresh approach to a longstanding problem.
The researchers start by looking for specific proteins secreted by breast cancer tumor cells across many thousands of samples drawn from breast cancer tumors. The team is searching for a signature set of proteins that can be detected in very low amounts. A vast data set and formidable computing power are essential for finding the precise biomarkers that could, in five to 10 years, lead to the blood test. Recently upgraded mass spectrometry equipment at Temple’s School of Pharmacy allows him to carry out this innovative research.
The promise of this research extends even beyond the hopes of early detection into the possibility of new, more effective medicines to battle breast cancer. Going forward, biomarkers are likely to be an increasingly hot topic for those in the pharmaceutical industry, which represents a significant part of the U.S. economy. Biomarkers such as these are often used as a reference point in drug development; when the biomarkers diminish or disappear in blood tests, it’s evidence that the new drug is working.
Current treatments for breast cancer are effective, but they come with their own health risks and side effects, some of which lead to different health challenges years after patients have recovered from cancer. The identification of these biomarkers would also mean that, in addition to early intervention, a breast cancer patient could get a form of personalized medicine, which is another area of potential business growth for the pharmaceutical industry. For patients, that might mean fewer side effects and complications down the line.
“It’s rare to find a scientist with a business background,” says Perez-Leal. He praises the Innovation Management and Entrepreneurship program with helping him take an idea, establish a business plan, and pitch to investors. “The research community should continue to focus on finding solutions and products to real problems.”
Clearly, breast cancer is a real problem, as the most common cancer among women: one in eight will face a diagnosis in her lifetime. But if Barrero and Perez-Leal succeed, it will be a game-changing advance. Many more women will be diagnosed in cancer’s earliest stages, receive more personalized treatment, overcome the disease, and lead long and healthy lives.
This story was originally published in On the Verge, the Fox School’s flagship research magazine. For more stories, visit www.fox.temple.edu/ontheverge.
Americans are growing older—and their caretakers need to decide the best and most cost effective way to care for them.
Since 2011, nearly 77 million baby boomers have become eligible for Medicare. For the elderly and those suffering from chronic diseases, home healthcare (HHC) is a convenient and cost-effective solution that avoids the necessity of receiving care through hospitals and nursing homes.
HHC meets an important demand in the healthcare system. Experts have found that close to 90 percent of Americans wish to spend their final time at home. But how does the care HHC providers deliver compare to that of larger health institutions?
Last year, In collaboration with investigators at the University of California at Irvine, Dr. Jacqueline Zinn, professor in the Fox School’s Department of Risk, Insurance and Healthcare Management, has received a five-year grant from the National Institute of Health to investigate the cost effectiveness and quality of care provided by home healthcare agencies.
Over the last decade, the home healthcare field has seen dramatic increases in patients, care providers, and spending. The New York Times reported that individual states spend close to $200 billion of their own funds on Medicaid, making it the second biggest item within their budgets.
As projections continue to rise and healthcare technology advances, patients should be aware of their care options.
“What we don’t know is whether or not the technologies that lead to additional growth impact the quality of care delivered,” said Zinn. “In other words, do larger facilities have better quality associated with growth? What is the optimal [home healthcare] agency size with respect to cost and quality? These are the questions we hope to answer.”
Home healthcare not only includes rehabilitative care after surgery, but hospice care and palliative care, which is dedicated to relieving people’s physical and emotional symptoms after facing life-threatening illnesses.
“Healthcare is on track to become 20 percent of the GDP,” said Zinn. “That means one in every five dollars generated by the U.S. economy will be in the healthcare sector.”
Alongside her fellow researchers at the UC Irvine, Zinn aims to discover valuable insights for patients, government, and health institutions, and home healthcare agencies alike by learning more about this under-researched field.
Are you interested in the intersection of healthcare and business education? Read our article, “Why More Surgeons and Health Professionals Are Pursuing MBAs” and learn more about Fox School Research.
Healthcare in this United States is a lightning rod for debate. As Congress grapples with the future of the Affordable Care Act, the American people face uncertainty in medical care and costs.
To improve the efficiency, quality, and cost-effectiveness for patient care, hospitals have increasingly turned digital, using Electronic Medical Record (EMR) systems to store and share patient’s medical history. However, as the use of EMR systems increased, so did reported healthcare costs.
Since the adoption of the physician coding systems used to store and update EMRs in 2009, Medicare has experienced an estimated $380 million increase in reimbursements per year. Medicare accused hospitals of “upcoding,” or illegally overstating patients’ diagnoses and treatment, in an effort to receive a higher reimbursement. A 2012 study showed that hospitals in Utica, NY, and Nashville, TN, increased its patient reimbursement claims by 43% and 82% respectively after adopting EMR systems.
In response to this drastic surge in reimbursements, the Centers for Medicare and Medicaid Services conducted a pilot program, the Recovery Audit Program, from 2004 to 2010. Researchers at the Fox School partnered with researchers at McGill University to study how this audit program has been able to reduce illegal Medicare reimbursement claims, thus lessening the financial burden on American taxpayers.
The initial goal of implementing EMRs was to lower costs by reducing medical errors, over-testing, and re-admissions. But the findings of Dr. Kartik K. Ganju of McGill and Drs. Hilal Atasoy and Paul Pavlou of Temple University, confirmed that the adoption of the coding system is associated with an increase in Medicare reimbursements, particularly in the case of for-profit hospitals.
The research found an average of $217,745 in inflated reimbursements to Medicare per hospital per year, and even higher costs (nearly $370,000 in overages) at for-profit hospitals. After finding $693 million in overpayments by Medicare in six pilot states, the audit program was adopted nationwide in 2010.
The researchers looked into this “trillion-dollar conundrum” and found that the audit program successfully combated upcoding by using default templates and by identifying and removing cloned records of old patient that were erroneously copied into a new patient’s medical chart. After the audit became nationwide, the study found that it had corrected up to $2 billion in incorrect claims; yet for-profit hospitals were still reporting high reimbursement fees than their nonprofit counterparts.
The bottom line? While EMRs have enhanced coordination and information sharing, they also make it easier to report expensive and potentially inappropriate healthcare expenses.
As the first successful evaluation of the Recovery Audit Program, the researchers praise the work that has been done, but warn that stronger oversight by the government is still needed to combat ever-increasing costs, especially at for-profit hospitals.
Learn more about Fox School Research.
Molly Belmont, a Risk Management and Insurance student from Temple University’s Fox School of Business, has been selected as the winner of the 2016 American Association of Managing General Agents (AAMGA) Student White Paper Research Contest.
A junior, Belmont won the AAMGA competition’s Technology and Wholesaler category for her paper, “Internet of Things Insurance, Opportunities, and Threats.”
In her paper, Belmont focused on three distinct areas – the connected home, the connected car, and the connected self – and discussed benefits and potential flaws in the collection of data through the Internet of Things IoT.
“While these devices can help insurance companies price better premiums and lower risk, and can also better educate the consumer and help them identify exactly what they’re paying for, there is a cyber risk involved with these devices that most companies didn’t necessarily consider,” said Belmont, a native of Malvern, Pa. “These systems can be hacked and create unforeseen dangers.”
Belmont said the paper was the culmination of more than one month’s work, during which time she utilized more than 20 sources. She said it was the first writing competition in which she’s taken the top prize. Belmont credited Fox School Assistant Professor Storm Wilkins with the encouragement to enter the competition.
For her winning entry, Belmont will receive a scholarship totaling $1,000; an all-expenses-paid trip and registration for the 90th AAMGA Annual Meeting, to be held May 22-25 at the JW Marriott Desert Ridge Resort in Scottsdale, Ariz.; an opportunity to shadow an AAMGA member during his or her meetings at the conference; and publication of her paper in the May issue of Wholesale Insurance News magazine, which is distributed to more than 1.4 million insurance professionals in more than 40 countries globally.
“I’ve been looking into the schedule of events and the networking opportunities available at the conference,” said Belmont, who this summer will serve as a benefits intern in the Philadelphia office of Arthur J. Gallagher & Co. “I wasn’t expecting to win, so it’s a big thrill.”
Pharmaceutical companies would improve sales revenue by investing in commercial operations that promote business innovation, employee engagement, organization alignment, and ensure a reasonable ratio between district sales managers and frontline sales representatives, according to Fox School of Business research.
The study was commissioned by TGaS Advisors, a benchmarking and advisory services firm, and division of KnowledgePoint360®, a global leader in communications, information and workflow services to healthcare professionals and the pharmaceutical and biotechnology industries.
“We focused on factors likely to impact pharmaceutical sales because data for this area are more robust, but the value of investments in sales operations should be read as a proxy for a broad range of commercial operation functions,” said George Chressanthis, the professor of healthcare management and marketing at the Fox School of Business who led the study team with Eric Eisenstein, assistant professor of marketing, and Fox PhD student Patrick Barbro.
According to Chressanthis, this is the first such independent research study on the effects of qualitative versus quantitative measures of commercial operation functions on business performance. Internally reported data from 26 pharmaceutical companies were analyzed for the period 2005-2011 and was complemented with qualitative survey data on commercial operations’ cultural attributes assessed by strategic account executives at TGaS Advisors.
The research team was given complete access to their database, with all analyses, findings, and recommendations independently developed of TGaS Advisors. All company specific data elements and names in the research were kept confidential, in keeping with contractual obligations, but did not affect the course the analysis.
The research showed that three factors within a company’s commercial operations organization are particularly important in determining U.S. business performance:
- Commercial operations’ cultural attributes, specifically innovativeness and responsiveness, which drive employee engagement and organizational alignment, are critical. These attributes are most powerful in affecting sales when working synergistically and in concert with quantitative investments in commercial operations support.
- Company scale and spending to support sales professionals that allow for more products to sell and leverage specialized commercial operations functional support for sales representatives to be more effective in their role.
- The number of sales representatives whom district sales managers supervise has a direct bearing on their ability to provide necessary levels of sales force effectiveness activities such as coaching, mentoring, on-the-job training, and managerial support to representatives, which in turn has a quantifiable impact on business performance.
The findings suggest that executives can significantly improve commercial performance by investing resources to:
- Create stronger alignment between functions and foster a culture of commercial innovation, organizational alignment, agility, and urgency. Quantitative investments in commercial operations will yield sub-optimal returns without the right structure of cultural attributes to support these business activities.
- Support improvements in sales professionals (i.e., through information, systems, business processes, training, etc.).
- Ensure an optimal number of sales representatives reporting to each first-line sales manager.
The Fox School research team has presented study findings at the following conferences: Pharmaceutical Management Science Association Annual Conference in May 2013 (Bonita Springs, Fla.), International Health Economics Association 9th World Congress in July 2013 (Sydney, Australia), and the American Marketing Association Summer Marketing Educators’ Conference in August 2013 (Boston).
Further insights from the study can be found by reading, “What Aspects of Commercial Operations Impact Pharmaceutical Company Business Performance?” and TGaS Advisors’ “Reflections on a Research Study Conducted by the Temple University Fox School of Business,” both available at www.tgas.com.